[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560-1160", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 66, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 49, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 631042, "exercisedValue": 0, "unexercisedValue": 285755}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 64, "title": "Chief Development Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 719206, "exercisedValue": 0, "unexercisedValue": 2986052}, {"maxAge": 1, "name": "Dr. Mark  Smythe Ph.D.", "age": 58, "title": "Founder & VP Technology", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling", "age": 52, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 59, "title": "Executive VP & Chief Drug Discovery and Preclinical Development Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 52, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Abha  Bommireddi", "title": "Executive Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 41.57, "open": 41.99, "dayLow": 40.07, "dayHigh": 41.99, "regularMarketPreviousClose": 41.57, "regularMarketOpen": 41.99, "regularMarketDayLow": 40.07, "regularMarketDayHigh": 41.99, "beta": 2.122, "trailingPE": 15.858268, "forwardPE": -25.175, "volume": 770101, "regularMarketVolume": 770101, "averageVolume": 942080, "averageVolume10days": 730700, "averageDailyVolume10Day": 730700, "bid": 40.27, "ask": 40.5, "bidSize": 200, "askSize": 100, "marketCap": 2362506496, "fiftyTwoWeekLow": 13.72, "fiftyTwoWeekHigh": 42.67, "priceToSalesTrailing12Months": 7.50114, "fiftyDayAverage": 33.5758, "twoHundredDayAverage": 26.017, "currency": "USD", "enterpriseValue": 2040334976, "profitMargins": 0.51471, "floatShares": 43065915, "sharesOutstanding": 58652100, "sharesShort": 3262628, "sharesShortPriorMonth": 3117841, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0556, "heldPercentInsiders": 0.01181, "heldPercentInstitutions": 1.04276, "shortRatio": 1.96, "shortPercentOfFloat": 0.056399997, "bookValue": 9.564, "priceToBook": 4.2116265, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 162110000, "trailingEps": 2.54, "forwardEps": -1.6, "enterpriseToRevenue": 6.478, "enterpriseToEbitda": 13.635, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PTGX", "underlyingSymbol": "PTGX", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "firstTradeDateEpochUtc": 1470922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "db1f1c69-f5b8-3245-b848-39f5038697fa", "gmtOffSetMilliseconds": -14400000, "currentPrice": 40.28, "targetHighPrice": 52.0, "targetLowPrice": 38.0, "targetMeanPrice": 46.8, "targetMedianPrice": 48.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 322635008, "totalCashPerShare": 5.501, "ebitda": 149643008, "totalDebt": 462000, "quickRatio": 15.611, "currentRatio": 15.724, "totalRevenue": 314952992, "debtToEquity": 0.082, "revenuePerShare": 5.308, "returnOnAssets": 0.21383, "returnOnEquity": 0.41748002, "freeCashflow": -154679248, "operatingCashflow": -63318000, "grossMargins": 1.0, "ebitdaMargins": 0.47513, "operatingMargins": 0.8092, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-29"}]